Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Nanosonics upgraded to Neutral from Underweight at JPMorgan » 08:30
11/24/22
11/24
08:30
11/24/22
08:30
NNCSF

Nanosonics

$2.96 /

+ (+0.00%)

JPMorgan analyst David…

JPMorgan analyst David Low upgraded Nanosonics to Neutral from Underweight with a A$4 price target.

ShowHide Related Items >><<
NNCSF Nanosonics
$2.96 /

+ (+0.00%)

NNCSF Nanosonics
$2.96 /

+ (+0.00%)

11/21/22 Canaccord
Nanosonics downgraded to Hold from Buy at Canaccord
02/09/22 JPMorgan
Nanosonics downgraded to Underweight from Neutral at JPMorgan
Downgrade
Nanosonics downgraded to Hold from Buy at Canaccord » 07:43
11/21/22
11/21
07:43
11/21/22
07:43
NNCSF

Nanosonics

$2.96 /

+ (+0.00%)

Canaccord analyst Elyse…

Canaccord analyst Elyse Shapiro downgraded Nanosonics to Hold from Buy with a price target of A$4.86, down from A$4.96, after the company hosted its annual general meeting, with which it provided a positive trading update for FY23 year-to-date and reaffirmed its calendar 2023 Coris launch. The positive meeting update and growth prospects are priced in at current levels, Shapiro contends.

ShowHide Related Items >><<
NNCSF Nanosonics
$2.96 /

+ (+0.00%)

NNCSF Nanosonics
$2.96 /

+ (+0.00%)

02/09/22 JPMorgan
Nanosonics downgraded to Underweight from Neutral at JPMorgan
Over a quarter ago
Hot Stocks
Nanosonics announces over 100M procedures performed with trophon devices » 09:16
06/08/22
06/08
09:16
06/08/22
09:16
NNCSF

Nanosonics

$2.45 /

+ (+0.00%)

Nanosonics announced that…

Nanosonics announced that patients in North America have been protected from the risk of ultrasound probe cross-contamination in over 100 million trophon high level disinfection procedures. "Our trophon technology has become the standard of care in North America for ultrasound probe infection control, evidenced by over 25,000 installations and partnerships with more than 5,000 health care facilities who trust us for their infection prevention," said Ken Shaw, President of the Americas for Nanosonics. "To date, more than 100 million trophon procedures have been performed in North America, and we believe this number will grow substantially, as there are still millions of procedures performed without the protection of trophon technology. Use of trophon HLD is fast gaining adoption globally due to data demonstrating its efficacy and real-life experience protecting more than 82,000 patients daily from risks of ultrasound probe cross-contamination."

ShowHide Related Items >><<
NNCSF Nanosonics
$2.45 /

+ (+0.00%)

02/09/22 JPMorgan
Nanosonics downgraded to Underweight from Neutral at JPMorgan
07/06/21 Goldman Sachs
Nanosonics downgraded to Sell from Neutral at Goldman Sachs
Downgrade
Nanosonics downgraded to Underweight from Neutral at JPMorgan » 07:12
02/09/22
02/09
07:12
02/09/22
07:12
NNCSF

Nanosonics

$3.62 /

+ (+0.00%)

JPMorgan analyst David…

JPMorgan analyst David Low downgraded Nanosonics to Underweight from Neutral with a A$4.05 price target.

ShowHide Related Items >><<
NNCSF Nanosonics
$3.62 /

+ (+0.00%)

07/06/21 Goldman Sachs
Nanosonics downgraded to Sell from Neutral at Goldman Sachs
02/25/21 JPMorgan
Nanosonics upgraded to Neutral from Underweight at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.